内部人交易雷达

美国 · SEC Form 4 · 快照日期： 2026-10-18 · 构建时间： 2026-10-18 · English

← 美国市场 · 覆盖记录

美国 · SEC FORM 4

Neuraxis, INC

NRXS · NYSE · CIK 0001933567 · Healthcare · Biotechnology

内部人信号

54.4 / 100

3 位买方 · 3 条买入交易行 · $12.3K 买入总额

为什么有这个信号？

买方广度中等
买入规模较低
角色中等
近期性较强
确信度较强
评分构成

每条进度条表示其对当前分数的贡献；权重和公式保持不变。

Cluster+21.0 / 35
买入规模+1.9 / 25
角色+13.0 / 20
近期性+8.5 / 10
确信度+10.0 / 10

哪些因素限制了当前分数？

  • ⚠ Cluster breadth is moderate · 3 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ 角色得分低 · 买入者中职位最高的是：Chief Executive Officer（CEO、董事长和持股 10% 以上的股东得分最低）
  • ✓ Recent activity · latest purchase 2026-10-08

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。

内部人活动时间轴

申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。

AprMayJunJulAugSepOct
Aharon GilDirector
○○○
Carrico Thomas JoesephCRO, CCO, CPO
○●
Carrico Brian AllenChief Executive Officer
○●
Miranda AdrianCMO, SVP Science & Tech
○
Watkins Bradley MitchellDirector
○
Keyser Jane ElizabethDirector
○
● 买入▼ 卖出○ 其他

Showing the six most active owners; 2 additional owner(s) remain in Form 4 申报证据.

买方广度与集中度

合资格买方3
买入集中度76%最大买方： Henrichs Timothy Robert · $9.4K
聚集买入 · 15天3 insiders峰值活动： 2026-10-08–2026-10-08

Roles in the peak window: CRO, CCO, CPO, Chief Executive Officer, Chief Financial Officer. Concentration uses priced qualifying P lines only and does not change the saved score.

信号历史

54.4 / 100

最新留档分数

↓ -0.3 pts相对上一个留档快照
  1. 55.1
  2. 55.0
  3. 54.8
  4. 54.7
  5. 54.4

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

近期 Form 4 活动

9买入
0卖出
15其他 Form 4 交易行
20SEC 申报 · 365天
买入3 qualifying P line(s) · 180 days
卖出0 sale line(s) · 仅供背景
其他11 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not detected in parsed evidence

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

市场背景

市场背景补充近期价格表现与风险信息，不影响内部人信号。

价格表现

1M
+17.1%
3M
-6.0%
6M
-3.9%
12M
+121.1%

波动率与流动性

波动率
94.6%
Beta
—
平均每日成交额
USD 723,019

估值

市值
USD 84.4M
P/E
—

基本面

利润率
-218.5%
ROE
-229.5%
细分行业
Biotechnology

市场数据

价格数据截至：2026-10-12 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值, 利润率, ROE · 财年截止日：2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-08-06 · Status: PASS

空头余额

空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。

空头股数
372,805
上期报告
377,067
日均成交量
235,996
回补天数
1.6

FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。

历史股票买入

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting owner类型证券股数平均价格估算金额来源
2026-10-08Henrichs Timothy Robert买入 (P)Common Stock1,937USD 4.84USD 9,375SEC 申报 ↗
2026-10-08Carrico Thomas Joeseph买入 (P)Common Stock328USD 4.84USD 1,588SEC 申报 ↗
2026-10-08Carrico Brian Allen买入 (P)Common Stock268USD 4.84USD 1,297SEC 申报 ↗
2026-04-01Henrichs Timothy Robert买入 (P)Common Stock7,593USD 1.96USD 14,882SEC 申报 ↗
2026-04-01Carrico Thomas Joeseph买入 (P)Common Stock667USD 1.96USD 1,307SEC 申报 ↗
2026-04-01Carrico Brian Allen买入 (P)Common Stock8,060USD 1.96USD 15,798SEC 申报 ↗
2026-02-12Hannasch Brian买入 (P)Common Stock40,000USD 4.92USD 196,800SEC 申报 ↗
2026-02-11Hannasch Brian买入 (P)Common Stock40,000USD 4.65USD 186,000SEC 申报 ↗
2025-12-23Aharon Gil买入 (P)Common Shares286,138USD 3.52USD 1,007,206SEC 申报 ↗
2025-07-01Hannasch Brian买入 (P)Common Stock355,556USD 2.25USD 800,001SEC 申报 ↗
2025-04-21Hannasch Brian买入 (P)Common Stock18,065USD 1.73USD 31,252SEC 申报 ↗

Form 4 申报证据

24 transaction lines in the latest 365-day window; 41 in local history.

日期申报人类型证券股数平均价格估算金额来源
2026-10-08Henrichs Timothy Robert买入 (P)Common Stock1,937USD 4.84USD 9,375SEC 申报 ↗
2026-10-08Carrico Thomas Joeseph买入 (P)Common Stock328USD 4.84USD 1,588SEC 申报 ↗
2026-10-08Carrico Brian Allen买入 (P)Common Stock268USD 4.84USD 1,297SEC 申报 ↗
展开近期 Form 4 证据 (22 grouped rows)
日期申报人类型证券股数平均价格估算金额来源
2026-10-08Henrichs Timothy Robert买入 (P)Common Stock1,937USD 4.84USD 9,375SEC 申报 ↗
2026-10-08Carrico Thomas Joeseph买入 (P)Common Stock328USD 4.84USD 1,588SEC 申报 ↗
2026-10-08Carrico Brian Allen买入 (P)Common Stock268USD 4.84USD 1,297SEC 申报 ↗
2026-08-24Miranda Adrian奖励／授予 (A)Common Stock199,106USD —USD —SEC 申报 ↗
2026-08-24Carrico Thomas Joeseph奖励／授予 (A)Common Stock193,678USD —USD —SEC 申报 ↗
2026-08-24Carrico Brian Allen奖励／授予 (A)Common Stock199,188USD —USD —SEC 申报 ↗
2026-08-13Watkins Bradley Mitchell奖励／授予 (A)Common Stock26,073USD 6.28USD 163,738SEC 申报 ↗
2026-08-13Keyser Jane Elizabeth奖励／授予 (A)Common Stock26,073USD 6.28USD 163,738SEC 申报 ↗
2026-08-13Ferge Kristin A奖励／授予 (A)Common Stock31,134USD 6.28USD 195,522SEC 申报 ↗
2026-08-13Aharon Gil奖励／授予 (A)Common Stock43,930USD 6.28USD 275,880SEC 申报 ↗
2026-07-29Aharon Gil奖励／授予 (A)Common Stock42,294USD —USD —SEC 申报 ↗
2026-04-28Aharon Gil奖励／授予 (A)Common Stock234,221USD —USD —SEC 申报 ↗
2026-04-01Henrichs Timothy Robert买入 (P)Common Stock7,593USD 1.96USD 14,882SEC 申报 ↗
2026-04-01Carrico Thomas Joeseph买入 (P)Common Stock667USD 1.96USD 1,307SEC 申报 ↗
2026-04-01Carrico Brian Allen买入 (P)Common Stock8,060USD 1.96USD 15,798SEC 申报 ↗
2026-02-12Hannasch Brian买入 (P)Common Stock40,000USD 4.92USD 196,800SEC 申报 ↗
2026-02-11Hannasch Brian买入 (P)Common Stock40,000USD 4.65USD 186,000SEC 申报 ↗
2026-01-22Watkins Bradley Mitchell奖励／授予 (A)Common Stock21,598USD 4.63USD 99,999SEC 申报 ↗
2026-01-22Keyser Jane Elizabeth奖励／授予 (A)Common Stock21,598USD 4.63USD 99,999SEC 申报 ↗
2026-01-22Ferge Kristin A奖励／授予 (A)Common Stock21,598USD 4.63USD 99,999SEC 申报 ↗
2026-01-22Aharon Gil奖励／授予 (A)Common Shares21,598USD 4.63USD 99,999SEC 申报 ↗
2025-12-23Aharon Gil买入 (P)Common Shares286,138USD 3.52USD 1,007,206SEC 申报 ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

快照与身份

快照日期2026-10-18
排名版本US-v1.2
数据质量PASS ELIGIBLE · —
股票代码NRXS
CIK0001933567
行业Healthcare
细分行业Biotechnology Yahoo Finance
SEC SIC3845 Electromedical & Electrotherapeutic Apparatus
交易所NYSE

数据覆盖

本地 Form 4 历史41 transaction lines from 2023-08-10 to 2026-10-08
11 P purchase lines · 3 S sale lines · 27 other lines
SEC 公司申报打开 SEC 申报 ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.